These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19080731)

  • 1. Novel nonstatin strategies to lower low-density lipoprotein cholesterol.
    Davidson MH
    Curr Atheroscler Rep; 2009 Jan; 11(1):67-70. PubMed ID: 19080731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon?
    Gadi R; Figueredo VM
    J Cardiovasc Med (Hagerstown); 2015 Jan; 16(1):1-10. PubMed ID: 25379719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies and new targets of treatment for familial hypercholesterolemia.
    Goldberg AC
    J Clin Lipidol; 2010; 4(5):350-6. PubMed ID: 21122677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapies to reduce low-density lipoprotein cholesterol.
    Wierzbicki AS; Viljoen A; Hardman TC; Mikhailidis DP
    Curr Opin Cardiol; 2013 Jul; 28(4):452-7. PubMed ID: 23736819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New targets and emerging therapies for reducing LDL cholesterol.
    Lilly SM; Rader DJ
    Curr Opin Lipidol; 2007 Dec; 18(6):650-5. PubMed ID: 17993811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic agents for lowering low density lipoprotein cholesterol.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):31-43. PubMed ID: 22465160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Other therapies for reducing low-density lipoprotein cholesterol: medications in development.
    Stein EA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):99-119. PubMed ID: 19217514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New lipid lowering agents].
    Cuevas A; Farías MM; Alonso R
    Rev Med Chil; 2014 Jul; 142(7):880-8. PubMed ID: 25378007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
    Seiki S; Frishman WH
    Cardiol Rev; 2009; 17(2):70-6. PubMed ID: 19367148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia.
    Samaha FF; McKenney J; Bloedon LT; Sasiela WJ; Rader DJ
    Nat Clin Pract Cardiovasc Med; 2008 Aug; 5(8):497-505. PubMed ID: 18506154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH).
    Muntoni S; Pisciotta L; Muntoni S; Bertolini S
    J Clin Lipidol; 2015; 9(1):103-6. PubMed ID: 25670367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
    Miyoshi T; Nakamura K; Doi M; Ito H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.